| Physiotherapy Treatment for Gynecological Cancer Survivors With Urinary Incontinence (NCT03957434) | Université de Sherbrooke | 2018-10-16 |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (NCT03488693) | Canadian Cancer Trials Group | 2018-10-16 |
| Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (NCT03635021) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2018-10-15 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (NCT06400238) | National Cancer Institute (NCI) | 2018-10-15 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| Impact of Sleep Extension in Adolescents (NCT03500458) | University of Colorado, Denver | 2018-10-15 |
| Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia (NCT03750409) | Baylor Research Institute | 2018-10-15 |
| Project My Heart Your Heart: Pacemaker Reuse (NCT04016870) | University of Michigan | 2018-10-13 |
| EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers (NCT03777384) | Sanford Health | 2018-10-12 |
| Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study (NCT06350734) | Mayo Clinic | 2018-10-12 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311) | National Cancer Institute (NCI) | 2018-10-12 |
| Hydrops: Diagnosing & Redefining Outcomes With Precision Study (NCT03412760) | University of California, San Francisco | 2018-10-11 |
| Risk Factors in Tachycardiomyopathy (NCT03418467) | University Hospital Tuebingen | 2018-10-11 |
| A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (NCT03602859) | Tesaro, Inc. | 2018-10-11 |
| Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (NCT03679650) | Beth Israel Deaconess Medical Center | 2018-10-11 |
| Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery (NCT03997162) | City of Hope Medical Center | 2018-10-11 |
| Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer (NCT03759431) | Centre hospitalier de l'Université de Montréal (CHUM) | 2018-10-11 |
| Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy (NCT03603795) | French Innovative Leukemia Organisation | 2018-10-11 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) (NCT03689699) | Mark Stein | 2018-10-11 |
| Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT (NCT04081428) | NHS Lothian | 2018-10-11 |
| Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (NCT03616587) | AstraZeneca | 2018-10-11 |
| Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (NCT06190600) | The Greater Poland Cancer Centre | 2018-10-11 |
| A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NCT03576417) | Groupe Oncologie Radiotherapie Tete et Cou | 2018-10-10 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (NCT03539536) | AbbVie | 2018-10-10 |
| Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study (NCT04496362) | Baylor Research Institute | 2018-10-10 |
| Impact of Glaucoma and Visual Field Loss on Life Space (NCT03673644) | University of Alabama at Birmingham | 2018-10-09 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (NCT04487587) | The Clatterbridge Cancer Centre NHS Foundation Trust | 2018-10-09 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) (NCT06360588) | National Cancer Institute (NCI) | 2018-10-08 |
| A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (NCT06105619) | Beijing Pearl Biotechnology Limited Liability Company | 2018-10-08 |
| Project Health: Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program (NCT03710746) | Oregon Research Institute | 2018-10-08 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy (NCT03690388) | Exelixis | 2018-10-05 |
| Observational Study of Ostomy Consumers (NCT03715179) | Hollister Incorporated | 2018-10-04 |
| A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia (NCT03589326) | Takeda | 2018-10-04 |
| TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (NCT03737604) | University of California, Davis | 2018-10-04 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630) | National Cancer Institute (NCI) | 2018-10-04 |
| Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy (NCT03543189) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-03 |
| Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma (NCT03011671) | University of Chicago | 2018-10-03 |
| Palliative Thoracic ImmunoRT (NCT03705806) | University Health Network, Toronto | 2018-10-03 |
| Integrative Sequencing In Germline and Hereditary Tumours (NCT03857594) | University Health Network, Toronto | 2018-10-02 |
| Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer (NCT03531099) | Hospices Civils de Lyon | 2018-10-02 |
| Optimal Prostate Study (NCT03386045) | Royal North Shore Hospital | 2018-10-02 |
| Long Term Follow up of Children Enrolled in the REDvent Study (NCT03709199) | Children's Hospital Los Angeles | 2018-10-01 |
| The Nordic DeltaCon Trial for Displaced Proximal Humeral Fractures in Elderly (NCT03531463) | Oslo University Hospital | 2018-10-01 |
| BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function (NCT03646357) | Oslo University Hospital | 2018-10-01 |
| The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy (NCT03582891) | University of California, San Francisco | 2018-10-01 |
| Synergetic B-cell Immunomodulation in SLE - 2nd Study. (NCT03747159) | Leiden University Medical Center | 2018-10-01 |
| Impact of Mesenchymal Stem Cells in Knee Osteoarthritis (NCT03477942) | University Hospitals Cleveland Medical Center | 2018-10-01 |
| Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease (NCT03478566) | The Hospital for Sick Children | 2018-10-01 |
| Study of the Touch® Trapezo-metacarpal Prosthesis (NCT03611023) | Groupe Concepteur Touch | 2018-10-01 |
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer (NCT03641755) | Dana-Farber Cancer Institute | 2018-10-01 |
| An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury (NCT03590028) | University of Chicago | 2018-10-01 |
| Remplissage Versus Latarjet Coracoid Transfer for Recurrent Shoulder Instability (NCT03453710) | Western University, Canada | 2018-10-01 |
| CBF and NCF Changes With Brain Radiation (NCT03606421) | University Health Network, Toronto | 2018-10-01 |
| A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (NCT03693014) | Memorial Sloan Kettering Cancer Center | 2018-10-01 |
| Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study (NCT03584217) | University of Colorado, Denver | 2018-10-01 |
| Innovative Family Prevention With Latino Siblings in Disadvantaged Settings (NCT03706014) | Harvard University | 2018-09-29 |
| Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections (NCT03651154) | Ottawa Hospital Research Institute | 2018-09-28 |
| Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center (NCT03671226) | M.D. Anderson Cancer Center | 2018-09-28 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) (NCT03634540) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-27 |
| CART22 Alone or in Combination With huCART19 for ALL (NCT03620058) | University of Pennsylvania | 2018-09-27 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826) | National Cancer Institute (NCI) | 2018-09-27 |
| Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NCT03682068) | AstraZeneca | 2018-09-27 |
| CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) (NCT03566043) | REGENXBIO Inc. | 2018-09-27 |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (NCT03703297) | AstraZeneca | 2018-09-27 |
| Dissemination of the Cardiovascular Risk Service (NCT03660631) | Korey Kennelty | 2018-09-27 |
| Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease (NCT03793114) | University of Bergen | 2018-09-26 |
| Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (NCT03326336) | GenSight Biologics | 2018-09-26 |
| Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC (NCT03667820) | University of Texas Southwestern Medical Center | 2018-09-26 |
| Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma (NCT03656835) | Ohio State University Comprehensive Cancer Center | 2018-09-26 |
| A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma (NCT03671018) | Hoffmann-La Roche | 2018-09-25 |
| Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (NCT03573401) | Biofrontera Inc. | 2018-09-25 |
| Identification of Genetic Causes of Calcific Aortic Valve Disease (NCT04149600) | Beth Israel Deaconess Medical Center | 2018-09-25 |
| Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. (NCT03647878) | Ipsen | 2018-09-24 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer (NCT03624660) | University of Florida | 2018-09-24 |
| Clinical Trial of an MRI Based Patient Specific Focal Knee Resurfacing Implant (NCT03755388) | Universitaire Ziekenhuizen KU Leuven | 2018-09-20 |
| Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (NCT03485378) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-09-20 |
| Laser Vaginal Treatment for SUI (NCT03671694) | Sunnybrook Health Sciences Centre | 2018-09-19 |
| Reducing Lung CongestIon Symptoms in Advanced Heart Failure (NCT03499236) | V-Wave Ltd | 2018-09-19 |
| Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (NCT03664830) | City of Hope Medical Center | 2018-09-19 |
| Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients (NCT03665207) | KU Leuven | 2018-09-18 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218) | Emory University | 2018-09-18 |
| Joint Endoprostheses Can Succesfully Treat Disabling Osteoarthritis. However, Infection is an Important Cause of Failure. Adequate Diagnostics Remains Challenging. Combining Advanced Imaging With Next-generation Sequencing of Samples Obtained Endoscopically Should Aid in Mapping and Characterizing. (NCT07494630) | University Hospital, Ghent | 2018-09-18 |
| ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis (NCT03517436) | Edwards Lifesciences | 2018-09-18 |
| Multidisciplinary Treatment of Chronic Vulvar Pain (NCT03640624) | Norwegian University of Science and Technology | 2018-09-18 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643) | National Cancer Institute (NCI) | 2018-09-18 |
| Sepsis in the ICU-II (NCT04695119) | Linkoeping University | 2018-09-17 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (NCT03511196) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-17 |
| Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue (NCT03657628) | Dana-Farber Cancer Institute | 2018-09-17 |
| Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS (NCT03564873) | University of Colorado, Denver | 2018-09-17 |
| Impact of Fecal Microbiota Transplantation in Ulcerative Colitis (NCT03483246) | Assistance Publique - Hôpitaux de Paris | 2018-09-17 |
| A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors (NCT03707340) | Memorial Sloan Kettering Cancer Center | 2018-09-14 |
| Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (NCT03421288) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-09-14 |
| Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands (NCT04208100) | CynosureLutronic | 2018-09-13 |
| Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) (NCT03553836) | Merck Sharp & Dohme LLC | 2018-09-12 |
| SPARC Bladder Mapping and Training Study (NCT03452007) | University of Louisville | 2018-09-12 |
| Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship (NCT03674437) | Memorial Sloan Kettering Cancer Center | 2018-09-11 |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (NCT03478514) | Alliance Foundation Trials, LLC. | 2018-09-11 |
| Intestinal Inflammation in CF Patients (NCT04392544) | The Hospital for Sick Children | 2018-09-11 |
| Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis In the Treatment of Abdominal Aortic Aneurysms (NCT03743142) | Marc van Sambeek | 2018-09-11 |